Disclaimer: This content is for educational purposes only and is not a substitute for medical advice. This is an FDA-approved prescription medication. Consult your healthcare provider before starting, stopping, or changing any treatment.
What Dulaglutide Is and What It’s Approved For
Dulaglutide is a once-weekly injectable GLP-1 receptor agonist for type 2 diabetes. It mimics a natural hormone signal so insulin is released when glucose rises, not when it is low.
It is FDA-approved for adults and children 10+ with type 2 diabetes since 2014, with a 2020 label expansion for reduction of major adverse cardiovascular events. It is not FDA-approved for weight loss. This page covers its mechanism, dosing, side effects, and regulatory status.
Meet Dulaglutide, Precisely
Dulaglutide is a GLP-1 receptor agonist built as a fusion protein — two GLP-1–like peptides linked to an IgG4 Fc backbone. That architecture slows clearance and resists rapid enzymatic breakdown, which helps it last the week.
Each peptide segment mirrors native GLP-1 with small substitutions that fend off the DPP-4 enzyme. It’s made via recombinant DNA technology, so it’s synthetic but designed to echo an endogenous signal.
Regulatory status is straightforward: FDA-approved since 2014 for adults with type 2 diabetes, prescription-only. In 2020, its label expanded to include reduction of major adverse cardiovascular events, based on REWIND. It is also approved for pediatric patients aged 10+ with type 2 diabetes. It is not FDA-approved for weight loss, and average weight changes are modest compared with dedicated obesity medications.
How the Signal Works
Dulaglutide binds the GLP-1 receptor on pancreatic beta cells, alpha cells, and in the gut–brain axis. Inside beta cells, it raises cyclic AMP, which heightens insulin release when glucose rises. Translation: after you eat, insulin response is stronger and better timed.
At the same time, alpha cells dial down glucagon, trimming the liver’s glucose output after meals. In the gut, gastric emptying slows a bit, which blunts spikes and often reduces portion sizes without a willpower war. In the brain’s satiety centers, the message reinforces “that’s enough.”
Clinically, this shows up as smoother post-meal glucose, lower A1c, and gradual weight shifts for many adults with type 2 diabetes. In REWIND, dulaglutide reduced major cardiovascular events by 12% versus placebo in a broad population, many without established cardiovascular health concerns.
Dosing and How It’s Given
Dulaglutide has a half-life of about five days, which supports once-weekly subcutaneous dosing in the abdomen, thigh, or upper arm. There is no oral version.
Starting
Most adults begin at 0.75 mg once weekly to gauge tolerance.
Titration
If more A1c reduction is needed and tolerated, common steps are 1.5 mg, then 3.0 mg, up to a labeled maximum of 4.5 mg once weekly.
Practical mechanics
Timing is flexible as long as the same weekly cadence is kept, with a labeled window for missed doses. Early weeks can bring queasiness because gastric emptying slows; smaller, slower meals often help as the gut adapts.
Safety Signals to Know
Most side effects are gastrointestinal: nausea, early fullness, burping, and sometimes vomiting, diarrhea, or constipation. These often fade as dosing stabilizes.
On its own, dulaglutide has a low risk of hypoglycemia because its insulin boost is glucose-dependent. Pair it with insulin or sulfonylureas and the risk rises since those drugs can lower glucose regardless of meals. Mild injection-site reactions and small heart rate increases can occur.
Serious but uncommon risks include pancreatitis; persistent, severe abdominal pain needs urgent evaluation. Gallbladder issues can emerge, sometimes alongside rapid weight shifts. Rapid A1c drops may transiently worsen pre-existing diabetic retinopathy, a class effect worth flagging if eye disease is present.
Contraindications are specific: a personal or family history of medullary thyroid carcinoma or MEN2 is a no-go due to a boxed warning from rodent data. Significant gastroparesis, pregnancy, and breastfeeding are generally settings to avoid use. No renal dose adjustment is required, but vomiting and dehydration can stress kidneys, so monitoring matters.
How It Stacks Up
Within the GLP-1 family, dulaglutide offers weekly convenience compared with daily liraglutide, with strong A1c lowering and robust cardiovascular data. Versus semaglutide, average weight loss tends to be a bit less, while glycemic efficacy is competitive. Tirzepatide — a dual GIP/GLP-1 agonist — often delivers larger A1c and weight changes.
Weight effects with dulaglutide are typically modest and in the single-digit kilogram range, varying by dose and baseline — generally less than with obesity-dedicated GLP-1 regimens. Combination strategies can be complementary when mechanisms differ. Metformin limits hepatic glucose output. SGLT2 inhibitors increase urinary glucose excretion. GLP-1 RAs improve post-meal insulin dynamics and satiety. DPP-4 inhibitors are redundant with GLP-1 agonists and are typically not paired.
Regulatory Status and Sourcing
Dulaglutide is FDA-approved for adults and for children 10 years and older with type 2 diabetes and remains prescription-only. It is not approved for chronic weight management. As a complex biologic, it is manufactured under strict quality controls; compounded versions may not match quality, purity, or stability standards.
For athletes, policies evolve. GLP-1 receptor agonists are currently in the World Anti-Doping Agency’s monitoring program, not on the Prohibited List. Rules can change, and Therapeutic Use Exemptions may apply in some settings.
Summary
Dulaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes with a cardiovascular risk reduction indication based on the REWIND trial. It is also approved for pediatric patients aged 10+. It is not FDA-approved for weight loss. Side effects are usually gastrointestinal, with clear contraindications including medullary thyroid carcinoma history and MEN2. Patients considering this medication should discuss appropriateness, contraindications, and monitoring with a licensed clinician.
Regulatory and Availability Status
- Regulatory Status: FDA-approved for type 2 diabetes with cardiovascular risk reduction indication
- Research Stage: Approved and marketed
- Availability: Prescription only
Disclaimer: This content is for educational purposes only and is not a substitute for medical advice. This is an FDA-approved prescription medication. Consult your healthcare provider before starting, stopping, or changing any treatment.
.svg)
.avif)